| In millions, except per share items | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Pharmaceutical | 55.1 | | | | | | | |
| Medical devices | 25.6 | | | | | | | |
| Total revenues [+] | 30.7 | 32.0 | 320.1 | 244.3 | 590.4 | 581.2 | 456.3 | 380.9 |
| Licensing | | | | | 0.7 | 0.6 | 1.5 | |
| Net interest income | | 2.3 | 17.7 | 30.4 | 36.2 | 48.0 | 19.0 | 6.4 |
| Revenue growth | -4.1% | -90.0% | 31.0% | -58.6% | 1.6% | 27.4% | 19.8% | 5.2% |
| Cost of goods sold [+] | 17.3 | 13.6 | 30.5 | 16.1 | 0.0 | 0.0 | 0.0 | 0.0 |
| Amortization of intangibles | | | 24.7 | 12.0 | | | | |
| Gross profit | 13.4 | 18.5 | 289.5 | 228.2 | 590.4 | 581.2 | 456.3 | 380.9 |
| Gross margin | 43.7% | 57.7% | 90.5% | 93.4% | 100.0% | 100.0% | 100.0% | 100.0% |
| Selling, general and administrative [+] | 45.1 | 40.0 | 63.3 | 40.3 | 36.1 | 34.9 | 29.8 | 25.5 |
| Sales and marketing | 6.8 | 6.3 | 17.7 | 0.5 | | | | |
| General and administrative | 38.3 | 33.7 | 45.6 | 39.8 | 36.1 | 34.9 | 29.8 | 25.5 |
| Other selling, general and administrative | | | | | | | | |
| Research and development | 7.4 | 2.8 | 7.4 | 3.8 | | | | |
| Other operating expenses | | | 25.0 | -3.7 | | | | |
| EBITDA [+] | -37.7 | -22.5 | 220.8 | 199.8 | 554.4 | 546.2 | 426.1 | 356.4 |
| EBITDA growth | 67.6% | -110.2% | 10.5% | -64.0% | 1.5% | 28.2% | 19.6% | 3.3% |
| EBITDA margin | -122.6% | -70.2% | 69.0% | 81.8% | 93.9% | 94.0% | 93.4% | 93.6% |
| Depreciation | 1.4 | 1.9 | 2.4 | 0.0 | 0.0 | -0.1 | -0.4 | 0.9 |
| EBITA | -39.1 | -24.3 | 218.5 | 199.8 | 554.4 | 546.3 | 426.5 | 355.4 |
| EBITA margin | -127.2% | -76.0% | 68.3% | 81.8% | 93.9% | 94.0% | 93.5% | 93.3% |
| Amortization of intangibles | 1.3 | 1.3 | 24.7 | 12.0 | | | | |
| EBIT [+] | -40.4 | -25.6 | 193.8 | 187.8 | 554.4 | 546.3 | 426.5 | 355.4 |
| EBIT growth | 57.5% | -113.2% | 3.2% | -66.1% | 1.5% | 28.1% | 20.0% | 3.4% |
| EBIT margin | -131.4% | -80.0% | 60.5% | 76.9% | 93.9% | 94.0% | 93.5% | 93.3% |
| Non-recurring items [+] | 10.8 | 8.6 | | 58.4 | 4.0 | | | |
| Asset impairment | 10.8 | 8.2 | | 3.7 | | | | |
| Loss (gain) on sale of assets | | | | 51.1 | 4.0 | | | |
| Unusual expense | | 0.4 | | | | | | |
| Interest expense, net [+] | 5.4 | 6.1 | 18.6 | 17.7 | 26.7 | 38.9 | 24.6 | 28.3 |
| Interest expense | 11.4 | 12.2 | 20.2 | 18.3 | 27.1 | 39.2 | 24.9 | 29.0 |
| Interest income | 6.0 | 6.1 | 1.7 | 0.6 | 0.4 | 0.3 | 0.2 | 0.8 |
| Other income (expense), net [+] | -5.0 | 0.8 | 9.3 | -2.4 | 6.5 | -6.1 | | |
| Gain (loss) on investments | | 0.8 | | | | | | |
| Gain (loss) on debt retirement | -8.4 | | | -2.4 | 6.5 | -6.1 | | |
| Gain (loss) on acquisitions / transactions | | | 9.3 | | | | | |
| Other | | | | | | -45.0 | -24.6 | -28.3 |
| Pre-tax income | -61.4 | -39.5 | 184.5 | 109.4 | 530.1 | 501.3 | 401.9 | 327.1 |
| Income taxes | -4.4 | -6.8 | 73.8 | 45.7 | 197.3 | 179.0 | 137.3 | 115.5 |
| Tax rate | 7.1% | 17.1% | 40.0% | 41.8% | 37.2% | 35.7% | 34.2% | 35.3% |
| Minority interest | -0.3 | | 0.0 | 0.1 | | | | |
| Earnings from continuing ops | -56.8 | -32.8 | 110.7 | 63.6 | 332.8 | 322.2 | 264.5 | 211.7 |
| Earnings from discontinued ops | -13.6 | -36.1 | | | | | | |
| Net income | -70.4 | -68.9 | 110.7 | 63.6 | 332.8 | 322.2 | 264.5 | 211.7 |
| Net margin | -229.3% | -215.0% | 34.6% | 26.0% | 56.4% | 55.4% | 58.0% | 55.6% |
| |
| Basic EPS [+] | ($0.48) | ($0.22) | $0.71 | $0.39 | $2.04 | $2.04 | $1.89 | $1.52 |
| Growth | 112.9% | -131.6% | 83.5% | -80.9% | 0.0% | 7.7% | 24.9% | 6.1% |
| Diluted EPS [+] | ($0.48) | ($0.22) | $0.71 | $0.39 | $2.03 | $1.86 | $1.66 | $1.45 |
| Growth | 112.9% | -131.7% | 83.0% | -81.0% | 9.3% | 12.1% | 14.8% | 28.7% |
| |
| Dividends per share [+] | $0.00 | $0.00 | $0.00 | $0.10 | $0.60 | $0.60 | $0.60 | $0.60 |
| Growth | -77.0% | -76.9% | -98.6% | -83.3% | 0.0% | 0.0% | 0.0% | 0.0% |
| |
| Shares outstanding (basic) [+] | 118.6 | 145.7 | 155.4 | 163.8 | 163.4 | 158.2 | 139.8 | 139.7 |
| Growth | -18.6% | -6.3% | -5.1% | 0.3% | 3.3% | 13.1% | 0.1% | 0.0% |
| Shares outstanding (diluted) [+] | 118.6 | 145.7 | 156.3 | 164.2 | 163.6 | 173.1 | 159.3 | 146.4 |
| Growth | -18.6% | -6.8% | -4.8% | 0.4% | -5.5% | 8.6% | 8.8% | -17.5% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |